CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| S1605 | SWOG | Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1607 | SWOG | A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1608 | SWOG | Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1609 | SWOG | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1612 | SWOG | A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1613 | SWOG | A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1614 | SWOG | A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors | Cancer Prevention and Control CIRB | Available to Open |
| S1616 | SWOG | A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1619 | SWOG | A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1701 | SWOG | A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |